Sanofi Makes Strategic Equity Investment in Resalis Therapeutics

In The News
October 30, 2024

Ropes & Gray advised Sanofi in a strategic equity investment in Torino, Italy-based Resalis Therapeutics. Resalis plans to use the proceeds to advance development of its lead candidate RES-010 through a Phase 2 clinical trial for a therapy targeting the molecular pathways underlying obesity and metabolic diseases. The transaction was announced on October 28.

The Ropes & Gray team included life sciences licensing associates Daniel Freshman, Amanda White and Ryan Kramer and life sciences licensing partner Abigail Gregor.